Journal
DIABETES CARE
Volume 39, Issue 3, Pages 465-468Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc15-2124
Keywords
-
Categories
Funding
- U.S. Department of Agriculture [CRIS 6250-51000]
- National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [SBIR1R44-DK-096715, 2/06/2014-2/05/16]
- Helmsley Charitable Trust
Ask authors/readers for more resources
OBJECTIVETo evaluate mini-dose glucagon in adults with type 1 diabetes using a stable, liquid, ready-to-use preparation.RESEARCH DESIGN AND METHODSTwelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 g of nonaqueous glucagon. Plasma glucose, glucagon, and insulin concentrations were measured. At 180 min, subjects received insulin followed in 60 min by a second identical dose of glucagon.RESULTSMean (SE) fasting glucose concentrations (mg/dL) were 110 +/- 7, 110 +/- 10, and 109 +/- 9 for the 75-, 150-, and 300-g doses, respectively, increasing maximally at 60 min by 33, 64, and 95 mg/dL (all P < 0.001). The post-insulin administration glucose concentrations were 70 +/- 2, 74 +/- 5, and 70 +/- 2 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P < 0.02) at 45-60 min.CONCLUSIONSSubcutaneous, nonaqueous, ready-to-use G-Pen Mini glucagon may provide an alternative to oral carbohydrates for the management of anticipated, impending, or mild hypoglycemia in adults with type 1 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available